The Efficacy of Aspirin in the Postoperative Period in Vascular Surgery
NCT ID: NCT01432652
Last Updated: 2015-07-29
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
45 participants
OBSERVATIONAL
2011-09-30
2014-05-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Antiplatelet Effect of Low Doses of Aspirin Taken Every 12 Hours in Patients Undergoing Coronary Artery Bypass Graft and/or Aortic Valve Surgery
NCT01466452
Aspirin Responsiveness and Outcome in Coronary Artery Bypass Graft (CABG) Surgery
NCT01174862
Effect of Aspirin on Hemostatic and Vascular Function After Live Fire Fighting
NCT01276691
Association of PeriOPerative Aspirin-ResisTance and CardioVascular Outcome
NCT04053894
Continuation of Aspirin Before Isolated Heart Valve Surgery
NCT05151796
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
In whole blood impedance aggregometry, the electrical impedance of the blood sample is measured by placing two electrodes in the recipient. After the addition of a platelet activator, the impedance will increase as platelets accumulate on the electrodes surfaces. Several activators, testing the patency of different platelet receptors can be used.
In this study, blood will be drawn on the day of surgery, and daily until the fifth postoperative day. Arachidonic acid, ADP, TRAP-6 and collagen will be used as activators. The first specifically tests the platelets reactivity to thromboxane A2. Aspirin inhibits this pathway, and the increase in impedance should therefore be limited in patients treated by this drug. The three other tests will be performed to evaluate the evolution of overall platelet reactivity in the postoperative period.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
COHORT
PROSPECTIVE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
vascular surgery
Patients undergoing vascular surgery
No interventions assigned to this group
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Patient aged 18 years or older.
* Patient treated by aspirin.
Exclusion Criteria
* Patient undergoing emergency surgery.
* Patient treated by a cox-inhibitor other than aspirin.
* Patient treated by omega-3-fatty acids.
* Patient treated by ADP or GPIIb/IIIa receptor inhibitor.
* Known coagulopathy, thrombopenia, thrombopathia or congenital or acquired thrombasthenia.
* Terminal renal insufficiency.
* Hepathic insufficiency.
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
University of Lausanne Hospitals
OTHER
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
University of Lausanne Hospitals
Lausanne, Canton of Vaud, Switzerland
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
176/11
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.